You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,060,978

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,060,978

Title:	Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist
Abstract:	Effective methods of treating a spinal disorder or osteoarthritis associated with a proinflammatory agent in a patient in need of such treatment, the method comprising administering an effective amount of DN-TNF (e.g., XPro.RTM.-1595) to a target tissue site at or near the spine or osteoarthritic joint to reduce pain and/or inflammation.
Inventor(s):	Binette; Francois (San Francisco, CA)
Assignee:	Warsaw Orthopedic, Inc. (Warsaw, IN)
Application Number:	13/280,073
Patent Claims:	1. A method of treating an intervertebral disc disorder by inhibiting a proinflammatory agent in a patient in need of such treatment, the method comprising administering 0.25 mg/kg to 20 mg/kg of a dominant negative tumor necrosis factor (DN-TNF) antagonist XPRO.RTM.-1595 to a target tissue site at or near the intervertebral disc to reduce pain, inflammation, and/or tissue destruction, wherein the proinflammatory agent comprises MMP-3, nitrous oxide, IL-1 or combinations thereof and the DN-TNF is administered in a drug depot comprising polymers comprising poly (lactide-co-glycolide) (PLGA) and polyethylene glycol (PEG) having a molar ratio of 4:1 and a pore forming agent, and the intervertebral disc disorder comprises disc compression, herniated disc, bulging disc, collapsed disc, degenerative disc, back pain, inflamed nerve or combinations thereof, and the DN-TNF antagonist is administered by a continuous infusion over 24 to 48 hours or the DN-TNF antagonist is released over at least 3 days to 6 months. 2. A method according to claim 1, wherein the DN-TNF antagonist is administered before, after or with etanercept, adalimumab, anakinra, infliximab or a combination thereof. 3. A method according to claim 1, wherein the DN-TNF is administered at or in the facet joint, annulus fibrosus, or the nucleus pulposus of the intervertebral disc.

Details for Patent 9,060,978

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998	⤷ Try a Trial	2039-02-26
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998	⤷ Try a Trial	2039-02-26
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999	⤷ Try a Trial	2039-02-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.